Video

Dr. Grisham on the Rationale for Binimetinib in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer.

Rachel N. Grisham, MD, section head of Ovarian Cancer and director of Gynecologic Medical Oncology at Memorial Sloan Kettering Cancer Center, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer (LGSOC).

The phase 3 MILO/ENGOT trial (NCT01849874) examined binimetinib (Mektovi) vs physician’s choice of chemotherapy in patients with recurrent LGSOC. Binimetinib was utilized on the trial because it is a MEK inhibitor that targets alterations in the MAPK pathway, and most alterations seen in LGSOC are those that impact this pathway, according to Grisham. This makes LGSOC molecularly distinct from high-grade serous disease, where alterations such as p53, homologous recombination deficiency, and BRCA, are more common. The alterations that most frequently occur in LGSOC are KRASBRAF V600E, and NF1, Grisham concludes.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Ami Umesh Badami, MD
Premal Thaker, MD, MS
Paul Chinfai Lee, MD, discusses the role of surgeons in regard to molecular testing in non–small cell lung cancer.
Neal D. Shore, MD, FACS